RECRUITING

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Talk to us

Conditions

Glaucoma, Primary Open AnglePrimary Open Angle Glaucoma (POAG)Optical Coherence Tomography Angiography (OCTA)CaffeineMacular Blood FlowPeripapillary Blood Flow

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.

Official Title

Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study

Quick Facts

Study Start:2018-12-30
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03675412

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * age 18 to 90 years
  2. * diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)
  3. * healthy subjects with no eye disease
  1. * Diseases, ophthalmic or systemic, that are likely to affect OCTA results
  2. * greater than moderate cataract
  3. * nystagmus
  4. * inability to look at target
  5. * macular degeneration other than mild drusen or pigmentary changes
  6. * diabetic retinopathy
  7. * neovascular glaucoma or non-glaucoma optic neuropathies
  8. * current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy
  9. * keratoconus, corneal ectasia, central corneal scarring
  10. * rheumatologic diseases or Raynaud's phenomena
  11. * pregnant and lactating women
  12. * mental illness or alcohol addiction
  13. * pre-existing bladder symptoms, cardiac disease or sleep disorder
  14. * refractive spherical diopter greater than 5 or cylinder greater than 3
  15. * possible tolerance to caffeine (drinking more than 1 cup coffee per day).

Contacts and Locations

Study Contact

M. Reza Razeghinejad, MD
CONTACT
215-928-7023
mrazeghi@willseye.org
Jeanne Molineaux, COA
CONTACT
215-825-4713
jmolineaux@gwillseye.org

Principal Investigator

M. Reza Razeghinejad, MD
PRINCIPAL_INVESTIGATOR
Wills Eye Hospital

Study Locations (Sites)

Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Wills Eye

  • M. Reza Razeghinejad, MD, PRINCIPAL_INVESTIGATOR, Wills Eye Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-12-30
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2018-12-30
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Primary Open Angle Glaucoma (POAG)
  • Optical Coherence Tomography Angiography (OCTA)
  • Caffeine
  • Macular Blood Flow
  • Peripapillary Blood Flow

Additional Relevant MeSH Terms

  • Glaucoma, Primary Open Angle